Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2009-10-5
pubmed:abstractText
Bi-acetylated l-stepholidine (l-SPD-A), a novel derivate of l-stepholidine (l-SPD), possesses a pharmacological profile of D(1)/5-HT(1A) agonism and D(2) antagonism. In the present study, we examined the potential antipsychotic effect of l-SPD-A in a phencyclidine (PCP)-induced rat model of schizophrenia. Pretreatment with l-SPD-A blocked acute PCP-induced hyperlocomotion and reversed prepulse inhibition (PPI) deficits. Chronic l-SPD-A administration (i.p., 10mg/kg/day for 14 days) improved social interaction and novel object recognition impairments in rats that were pretreated with PCP (i.p., 5mg/kg/day for 14 days). Moreover, in a conditioned avoidance response (CAR) test, l-SPD-A, with either i.p. or oral administration, significantly decreased active avoidance without affecting the escape response of rats. Importantly, compared to that of the parent compound l-SPD, l-SPD-A showed stronger suppression of CARs. Lastly, using a [(35)S]GTPgammaS binding assay, we demonstrated that l-SPD-A improved impaired dopamine D(1) receptor function in the prefrontal cortex (PFC) in chronic PCP-treated rats. Taken together, these results indicate that l-SPD-A was not only effective against the hyperactivity, but also improved the sensorimotor gating deficit, social withdrawal and cognitive impairment in an animal model of schizophrenia. The present data suggest that l-SPD-A, a potential neurotransmitter stabilizer, is a promising novel candidate drug for the treatment of schizophrenia.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1573-2509
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
115
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
41-9
pubmed:dateRevised
2010-9-2
pubmed:meshHeading
pubmed-meshheading:19744833-Acoustic Stimulation, pubmed-meshheading:19744833-Analysis of Variance, pubmed-meshheading:19744833-Animals, pubmed-meshheading:19744833-Antipsychotic Agents, pubmed-meshheading:19744833-Avoidance Learning, pubmed-meshheading:19744833-Berberine, pubmed-meshheading:19744833-Disease Models, Animal, pubmed-meshheading:19744833-Dose-Response Relationship, Drug, pubmed-meshheading:19744833-Drug Interactions, pubmed-meshheading:19744833-Exploratory Behavior, pubmed-meshheading:19744833-Guanosine 5'-O-(3-Thiotriphosphate), pubmed-meshheading:19744833-Inhibition (Psychology), pubmed-meshheading:19744833-Interpersonal Relations, pubmed-meshheading:19744833-Locomotion, pubmed-meshheading:19744833-Male, pubmed-meshheading:19744833-Phencyclidine, pubmed-meshheading:19744833-Radioligand Assay, pubmed-meshheading:19744833-Rats, pubmed-meshheading:19744833-Rats, Sprague-Dawley, pubmed-meshheading:19744833-Receptors, Dopamine, pubmed-meshheading:19744833-Receptors, Serotonin, pubmed-meshheading:19744833-Recognition (Psychology), pubmed-meshheading:19744833-Schizophrenia, pubmed-meshheading:19744833-Startle Reaction
pubmed:year
2009
pubmed:articleTitle
Evaluation of the antipsychotic effect of bi-acetylated l-stepholidine (l-SPD-A), a novel dopamine and serotonin receptor dual ligand.
pubmed:affiliation
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't